Organisation paid for research Program year 2024 Source: CMS Open Payments

Coastal Carolina Research Ctr

Neither a doctor nor a teaching hospital

Research payments

$7,480,551

919 payments

Through program year 2024, Coastal Carolina Research Ctr is reported as receiving $7,480,551 in research payments, across 919 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $1,417,392 65
2023 Research $2,254,257 595
2022 Research $2,688,942 192
2021 Research $1,119,960 67

Breakdown

Who paid Research payments · program years 2021–2024
  1. Moderna TX, Inc. $7,476,794 907 payments
  2. Pfizer Inc. $3,757 12 payments
Studies the money was for Research payments · program years 2021–2024
  1. A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older $5,322,401 276 payments
  2. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $943,681 487 payments
  3. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Mrna-1403, A Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults 18 Years of Age $467,240 8 payments
  4. A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults $382,499 45 payments
  5. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $113,998 35 payments
  6. A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 $94,785 11 payments
  7. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $92,362 30 payments
  8. A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 $25,239 4 payments
  9. A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults $18,649 5 payments
  10. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age $15,940 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record